Procoagulant and calcium carbonate / gelatin embolization microspheres as well as preparation method and application thereof
By using procoagulant-@calcium carbonate/gelatin embolization microspheres in interventional treatment of liver cancer, combined with aortic embolization and vascular occlusion, the release of calcium ions and thrombin is triggered by the tumor's acidic microenvironment, achieving comprehensive embolization and immune activation of blood vessels of different sizes. This solves the problems of poor embolization effect and tumor microenvironment deterioration in existing technologies, thus improving the treatment effect of liver cancer.
Patent Information
- Application Number
- CN202310497106.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-05
- Publication Date
- 2024-11-15
AI Technical Summary
In current interventional treatments for liver cancer, embolization microspheres cannot effectively embolize blood vessels of different sizes simultaneously, and the tumor microenvironment deteriorates further after embolization, affecting the treatment outcome.
The method employs procoagulant-@calcium carbonate/gelatin embolization microspheres to embolize the aortic vessels of liver tumors. The tumor's acidic environment triggers the release of calcium ions and procoagulant, synergistically enhancing microvascular thrombosis. Combined with calcium carbonate neutralizing the tumor's acidic environment, it regulates immunosuppression, achieving comprehensive embolization and immune activation.
It achieves comprehensive embolization of tumor vessels of different sizes, inhibits tumor growth, activates anti-tumor immune response, and improves the therapeutic effect of tumor embolization.
Smart Images

Figure CN118949065A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedical materials, and in particular relates to a procoagulant calcium carbonate / gelatin embolic microsphere and a preparation method and application thereof. Background Art
[0002] Primary liver cancer (mainly hepatocellular carcinoma, HCC) is one of the six most common malignant tumors in the world, with the characteristics of strong metastasis and high malignancy. China is a country with a high incidence of liver cancer. More than half of the new and fatal liver cancer cases in the world occur in China, and the incidence and mortality rates are still increasing year by year. Therefore, my country faces huge challenges in the diagnosis and treatment of liver cancer. In recent years, the clinical treatment methods for primary liver cancer mainly include surgery, interventional therapy, chemotherapy, radiotherapy, ablation therapy, liver transplantation, etc. Among them, interventional therapy has gradually become the first choice for large liver cancer that cannot be surgically removed due to its advantages of precise efficacy, less trauma, and fast recovery. It is currently the most commonly used treatment method for liver cancer. Interventional treatment of liver cancer, including transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE), is a method of inserting embolic materials directly into the blood supply artery of the tumor in the liver through extracorporeal vascular puncture and catheterization with the help of medical imaging methods. The blood supply artery is embolized to cut off the oxygen and nutrient supply to the tumor, thereby inhibiting tumor growth. Compared with traditional surgical resection, TAE therapy causes less damage to patients, can reduce patients' pain, and improve patients' quality of life. Therefore, interventional embolization therapy has received more and more attention in the clinical treatment of liver cancer.
[0003] At present, the embolic materials used in clinical interventional treatment of liver cancer mainly include liquid embolic agents and solid embolic particles. Iodized oil as a liquid embolic agent can quickly flow to the tumor area for comprehensive embolization of tumor blood vessels. Solid embolic particles can stay in the tumor blood vessels to form mechanical embolism. Due to its variety, efficient drug loading and sustained release function, good efficacy, and few side effects, it has gradually become a hot research topic in liver cancer embolization treatment in recent years. Currently, common embolic particles mainly include gelatin sponge, starch microspheres, polyvinyl alcohol (PVA) particles or collagen microparticles. Among them, biologically derived gelatin sponge particles have been widely used in interventional embolization treatment of liver cancer due to their excellent biocompatibility, easy availability, and low price.
[0004] On the other hand, similar to interventional embolization, tumor vascular occlusion therapy is a cancer treatment method that inhibits tumor growth by blocking tumor blood vessels through in situ thrombosis. It has been widely studied due to its rapid onset and wide applicability. The Philip E. Thorpe team at the University of Texas Southwestern Medical Center first reported vascular occlusion therapy in 1997. Since then, various vascular coagulants have been developed, including vascular blockers, truncated tissue factor (tTF), thrombin, etc., which have achieved excellent tumor vascular occlusion treatment effects.
[0005] At present, there are many deficiencies and limitations in the embolic materials used for interventional treatment of clinical liver cancer. For example, iodized oil, as a traditional liquid embolic material, is easily washed away by the tumor artery during arterial embolization, resulting in poor long-term embolic effect and easy to cause liver lesions. At the same time, iodized oil is lipophilic, and the stability of the microemulsion formed by chemotherapy drugs and it is poor, which can easily lead to premature drug leakage, limit the chemotherapy effect, and easily produce toxic side effects. At present, embolic microspheres are mainly used for embolization of the aorta of liver tumors, and it is difficult to achieve comprehensive embolization of small-sized blood vessels including arterioles and capillaries. Moreover, after embolization, the tumor is prone to establish collateral circulation and obtain new blood supply, which can easily lead to recurrence and metastasis of liver tumors. In addition, after hepatic artery embolization, the blood supply in the tumor is blocked, resulting in the accumulation of metabolites such as lactic acid in the tumor tissue, which further deteriorates the microenvironment characteristics such as microacid in the tumor, and ultimately reduces the responsiveness of the tumor to various therapies including immunotherapy.
[0006] On the other hand, tumor vascular infarction treatment also has its shortcomings. For example, the tumor vascular thrombus formed by the current vascular embolic agents is usually fragile and unstable. A large number of studies have shown that single tumor vascular infarction treatment is difficult to cope with the complex tumor vascular system, especially the aorta with rich blood supply, which leads to poor tumor treatment effect.
[0007] Therefore, targeting the complex blood supply system of liver tumors, combining tumor interventional embolization therapy with vascular infarction therapy to achieve comprehensive embolization of liver tumor blood vessels of different sizes is of great significance for improving the efficacy of liver tumor treatment and inhibiting liver tumor metastasis. Summary of the invention
[0008] Therefore, the technical problem to be solved by the present invention is to overcome the problem in the prior art that embolic microspheres in the interventional treatment of liver cancer are difficult to simultaneously achieve embolization of blood vessels of different sizes and the embolization causes further deterioration of the tumor microenvironment.
[0009] In order to solve the above technical problems, the present invention provides a procoagulant @ calcium carbonate / gelatin embolic microspheres and a preparation method and application thereof. The calcium carbonate / gelatin embolic microspheres are used to embolize the aorta of the liver tumor, and the micro-acidic environment of the tumor is used to trigger the release of calcium ions and the loaded procoagulant, thereby synergistically enhancing the thrombosis of the tumor microvessels and achieving comprehensive embolization of tumor blood vessels of different sizes; in addition, calcium carbonate is used to neutralize the micro-acidic environment of the tumor and reverse the tumor immunosuppression, thereby improving the embolic treatment effect of the tumor.
[0010] The first object of the present invention is to provide a procoagulant @ calcium carbonate / gelatin embolic microspheres, comprising a procoagulant and calcium carbonate / gelatin embolic microspheres; the procoagulant is loaded into the calcium carbonate / gelatin embolic microspheres by adsorption, and the calcium carbonate / gelatin embolic microspheres comprise gelatin microspheres and calcium carbonate nanoparticles distributed in the gelatin microspheres;
[0011] The particle size of the calcium carbonate / gelatin embolic microspheres is 100 μm-800 μm; the particle size of the calcium carbonate nanoparticles is 80 nm-200 nm;
[0012] The procoagulant is selected from one or more of a vascular blocking agent, a truncated tissue factor and thrombin.
[0013] Furthermore, the particle size of the calcium carbonate / gelatin embolic microspheres is 100 μm-200 μm, 200 μm-300 μm, 300 μm-400 μm, 400 μm-500 μm, 500 μm-600 μm, 600 μm-700 μm, 700 μm-800 μm.
[0014] Preferably, the particle size of the calcium carbonate / gelatin embolic microspheres is 100 μm-200 μm.
[0015] In one embodiment of the present invention, the vascular blocker is one or more of DMXAA, cambridetin A4 phosphate (CA4P), flavone-8-acetic acid (FAA), plinabulin and omeprazole (AVE-8062); the truncated tissue factor is selected from one or more of MHCII antibody-tTF fusion protein, vascular endothelial cell adhesion factor antibody-tTF fusion protein, fibronectin antibody-tTF fusion protein, polypeptide-tTF fusion protein; the thrombin is derived from one or more of human plasma, bovine plasma, rabbit plasma and rat plasma.
[0016] Furthermore, the thrombin is derived from rat plasma and has an activity of 2000 U mg -1 .
[0017] The second object of the present invention is to provide a method for preparing the procoagulant @ calcium carbonate / gelatin embolic microspheres, using a microchannel reactor as a generating device, the microchannel reactor comprising a droplet generation tube, a dispersed phase input tube and a continuous phase input tube connected to the input end of the droplet generation tube, and a sample receiving tube connected to the output end of the droplet generation tube; the preparation method comprises the following steps:
[0018] S1, dissolving calcium carbonate nanoparticles in gelatin solution to obtain a dispersed phase;
[0019] Adding a surfactant to the oil phase to obtain a continuous phase;
[0020] S2, injecting the dispersed phase and the continuous phase described in S1 into the dispersed phase input tube and the continuous phase input tube respectively, so that the dispersed phase is sheared by the continuous phase in the droplet generation tube to obtain water-in-oil (W / O) calcium carbonate / gelatin droplets;
[0021] S3, adding a cross-linking agent to the water-in-oil calcium carbonate / gelatin droplets described in S2 for solidification, and obtaining calcium carbonate / gelatin embolic microspheres by freeze-drying;
[0022] S4. Add the calcium carbonate / gelatin embolic microspheres described in S3 to the procoagulant solution, and obtain the procoagulant@calcium carbonate / gelatin embolic microspheres after incubation.
[0023] In one embodiment of the present invention, the size of the droplet generating tube of the microchannel reactor is selected from 21G, 22G, 25G, 27G or 30G.
[0024] Furthermore, the size of the droplet generating tube is 30G.
[0025] In one embodiment of the present invention, in S1, the preparation of the calcium carbonate nanoparticles specifically includes the following steps: adding an equal volume of alkali solution to a calcium chloride solution (1.2M), mixing and introducing carbon dioxide gas until the mixed solution is neutral, and obtaining the calcium carbonate nanoparticles by centrifugation, washing, and freeze-drying.
[0026] Furthermore, the alkali solution is a sodium hydroxide solution.
[0027] In one embodiment of the present invention, in S1, the concentration of the gelatin solution is 5wt%-15wt%; the concentration of the calcium carbonate nanoparticles in the dispersed phase is 0.5wt%-5wt%; and the concentration of the surfactant in the continuous phase is 2wt%-10wt%.
[0028] Furthermore, the concentration of calcium carbonate nanoparticles in the dispersed phase is 1 wt %.
[0029] In one embodiment of the present invention, in S1, the surfactant is selected from one or more of Span 80, Span 60, Span 40, Span 20, Tween 20, sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, sodium oleate, lauryl alcohol polyoxyethylene ether and zinc stearate; the oil phase is selected from one or more of benzene, toluene, xylene, paraffin oil, petroleum ether, dodecane and hexadecane.
[0030] Furthermore, the surfactant is Span 80; and the oil phase is toluene.
[0031] In one embodiment of the present invention, in S2, the flow rate of the continuous phase is 100 Lmin -1 -300Lmin -1 ; The flow rate of the dispersed phase is 10 L min -1 -30Lmin -1 .
[0032] Furthermore, the flow rate of the continuous phase is 100 Lmin -1 ; The flow rate of the dispersed phase is 10Lmin -1 .
[0033] In one embodiment of the present invention, S2 also includes collecting the water-in-oil calcium carbonate / gelatin droplets discharged from the sample receiving tube through a glass bottle containing a continuous phase (droplet collection phase), and keeping the glass bottle in an ice bath condition during the collection process.
[0034] In one embodiment of the present invention, in S3, the cross-linking agent is one or more of formaldehyde, glutaraldehyde and genipin; the amount of the cross-linking agent is 2wt%-10wt% of the water-in-oil calcium carbonate / gelatin droplets;
[0035] In one embodiment of the present invention, in S3, the curing temperature is 20°C-40°C; and the curing time is 30min-120min.
[0036] Furthermore, the cross-linking agent is glutaraldehyde.
[0037] In one embodiment of the present invention, in S4, the concentration of the procoagulant solution is 5UmL -1 -30U mL -1 .
[0038] Furthermore, the concentration of the procoagulant solution is 25 U mL -1 .
[0039] In one embodiment of the present invention, in S4, the procoagulant solution is obtained by dissolving the procoagulant in a buffer solution.
[0040] Furthermore, the buffer is selected from one or more of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) buffer, PBS buffer, Tris-hydrochloric acid buffer and disodium hydrogen phosphate-citric acid buffer.
[0041] Preferably, the buffer is selected from 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) buffer (50 mM, 0.14 M NaCl, pH 7.6).
[0042] The third object of the present invention is to provide a use of the procoagulant@calcium carbonate / gelatin embolic microspheres in the preparation of in situ liver cancer embolic treatment agents.
[0043] In one embodiment of the present invention, the liver cancer model is an SD rat in situ liver cancer model.
[0044] In one embodiment of the present invention, the procoagulant@calcium carbonate / gelatin embolic microspheres in the application are a suspension (50% v / v).
[0045] In one embodiment of the present invention, in the application, the procoagulant@calcium carbonate / gelatin embolic microsphere suspension is injected into the hepatic artery through a catheter.
[0046] The technical solution of the present invention has the following advantages over the prior art:
[0047] (1) The coagulant@calcium carbonate / gelatin embolic microspheres described in the present invention are combined with vascular occlusion therapy to achieve comprehensive embolization of tumor vessels of different sizes and regulation of the slightly acidic environment by combining aortic interventional embolization with microvascular coagulation, and are used for efficient interventional embolization and coagulation combined treatment of in situ liver cancer. Among them, the preferred thrombin@calcium carbonate / gelatin embolic microspheres can trigger the release of calcium ions and thrombin in the slightly acidic environment of the tumor, and can synergistically promote the coagulation reaction, which can not only embolize the tumor aortic vessels, but also induce thrombosis in microvessels, thereby achieving comprehensive embolization of tumor vessels of different sizes and inhibiting tumor growth.
[0048] (2) The procoagulant @ calcium carbonate / gelatin embolic microspheres described in the present invention can not only embolize the aorta, but also, the slightly acidic environment of the tumor can further promote the release of calcium ions and thrombin, synergistically inducing the formation of thrombi in microvessels, thereby achieving comprehensive embolism of tumor vessels of different sizes and inhibiting tumor growth.
[0049] (3) The procoagulant @ calcium carbonate / gelatin embolic microspheres described in the present invention endow the gelatin embolic microspheres with micro-acid responsiveness, which can trigger the effective release of calcium ions and thrombin in the micro-acid environment of the tumor, thereby synergistically promoting the coagulation reaction. Calcium carbonate has a proton sponge effect, which can effectively neutralize the tumor acidic microenvironment that continues to deteriorate after embolization, regulate the immunosuppression of the tumor site, increase the proportion of effector immune cells in the tumor and the secretion of effector cytokines, thereby activating the anti-tumor immune response and further enhancing the therapeutic effect of tumor embolization.
[0050] (4) The procoagulant@calcium carbonate / gelatin embolic microspheres of the present invention include calcium carbonate nanoparticles, gelatin, and procoagulants, all of which have good biocompatibility and clinical transformation value. Among them, the raw materials for the production of calcium carbonate nanoparticles are simple and safe, reaching the medical grade level.
[0051] (5) The preparation method described in the present invention can be used for efficient loading and slightly acid-responsive release of procoagulants. The system has abundant raw materials, and the synthesized embolic microspheres have uniform particle size and are easy to store, which is suitable for mass production. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:
[0053] Figure 1 This is a scanning electron micrograph of calcium carbonate nanoparticles prepared in Example 1 of the present invention;
[0054] Figure 2 This is an optical photograph of the calcium carbonate / gelatin embolic microspheres prepared in Example 1 of the present invention;
[0055] Figure 3 The scanning electron microscope image of the calcium carbonate / gelatin embolic microspheres prepared in Example 1 of the present invention and the corresponding elemental spectrum;
[0056] Figure 4 This is a scanning electron microscopic image of the gelatin embolic microspheres prepared in Example 1 of the present invention;
[0057] Figure 5 The optical photographs of calcium carbonate / gelatin embolic microspheres of different sizes in Example 1 of the present invention;
[0058] Figure 6 This is a comparison chart of the water absorption rates of the calcium carbonate / gelatin embolic microspheres and the gelatin embolic microspheres in Example 1 of the present invention;
[0059] Figure 7 This is a comparison chart of the swelling rates of the calcium carbonate / gelatin embolic microspheres and the gelatin embolic microspheres in Example 1 of the present invention;
[0060] Figure 8 This is a graph showing the change in calcium ion release over time of calcium carbonate / gelatin embolic microspheres in different pH buffers in Example 1 of the present invention;
[0061] Fig. 9 The graph is a curve of the change in solution pH after the calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres were co-incubated with a pH 6.5 hydrochloric acid aqueous solution in Example 1 of the present invention;
[0062] Fig.10 This is a graph showing the loading efficiency of thrombin by calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres in Example 2 of the present invention;
[0063] Fig.11 This is a graph showing the change in the amount of thrombin released over time in thrombin@calcium carbonate / gelatin embolic microspheres in different pH buffers in Example 2 of the present invention;
[0064] Fig.12 This is a graph showing the change in the amount of thrombin released by thrombin@gelatin embolic microspheres in different pH buffers over time in Example 2 of the present invention;
[0065] Fig.13 This is a hemolysis diagram of calcium carbonate / gelatin embolic microspheres in Example 2 of the present invention;
[0066] Fig.14 This is a graph of relative cell viability of calcium carbonate / gelatin embolic microspheres in Example 2 of the present invention;
[0067] Fig.15 The graph of promoting coagulation of calcium chloride, thrombin and a mixture of the calcium chloride, thrombin and the ...
[0068] Fig.16 It is a statistical graph of the absorbance change of hemoglobin after the gelatin embolic microspheres, thrombin@gelatin embolic microspheres, calcium carbonate / gelatin embolic microspheres and thrombin@calcium carbonate / gelatin embolic microspheres were subjected to the procoagulant experiment under different pH conditions in Example 2 of the present invention;
[0069] Fig.17 is a graph showing the tumor growth of rats after different embolization treatments in Example 3 of the present invention;
[0070] Fig.18 This is an H&E stained section of a rat tumor 4 hours after different embolization treatments in Example 3 of the present invention;
[0071] Fig.19 This is a statistical diagram of the changes in pH fluorescence ratio of rat tumors after different embolization treatments for 24 hours in Example 3 of the present invention;
[0072] Fig. 20 The CD8 +Statistical chart of changes in T lymphocyte content;
[0073] Fig.21 This is a statistical diagram of changes in the content of NK cells in tumors after different embolization treatments in Example 4 of the present invention;
[0074] Fig. 22 This is a statistical diagram of the secretion level of IFN-γ in the tumor after different embolization treatments in Example 4 of the present invention;
[0075] Fig.23 This is a statistical chart of changes in serum IFN-γ content after different embolization treatments in Example 4 of the present invention;
[0076] Fig.24 This is a statistical chart of changes in serum TNF-α content after different embolization treatments in Example 4 of the present invention;
[0077] Fig.25 A schematic diagram of the mechanism of action of the procoagulant @ calcium carbonate / gelatin embolic microspheres of the present invention for combined interventional embolic therapy and vascular occlusion therapy for liver cancer treatment;
[0078] Among them, the p value was calculated by one-way analysis of variance with Tukey's multiple comparisons; "ns" indicates no significant difference, "*" indicates P < 0.05, "**" indicates P < 0.01, and "***" indicates P < 0.001. DETAILED DESCRIPTION
[0079] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0080] The reaction device involved in the present invention:
[0081] The microchannel reactor is used as a generating device, and comprises a droplet generating tube, a dispersed phase input tube and a continuous phase input tube connected to the input end of the droplet generating tube, and a sample receiving tube connected to the output end of the droplet generating tube.
[0082] Information on materials involved in the present invention:
[0083] Calcium chloride, sodium hydroxide, anhydrous ethanol, glutaraldehyde, and toluene were purchased from China National Pharmaceutical Group Chemical Reagent Co., Ltd. Span 80 (brand: Aladdin, item number: s110839-1l), 4-hydroxyethylpiperazineethanesulfonic acid (brand: Acros, item number: C32985.36), gelatin (brand: Sigma-Aldrich, item number: v900863-100g), and thrombin from rat plasma (brand: sigma-aldrich, item number: T5772-1KU, activity 2000U mg -1 ), fibrinogen (brand: Sigma-Aldrich, catalog number: f3879-250mg), Cy5.5 mono N-hydroxysuccinimide ester (Cy5.5-NHS, brand: ApexBio, catalog number: a8103-25mg), fluorescent isothiocyanate mono N-hydroxysuccinimide ester (FITC-NHS, brand: ThermoFisher, catalog number: 46409), 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF, brand: ApexBio, catalog number: c5694-500ug). Flow cytometry antibodies were purchased from Biolegend: FITC anti-rat CD3 (clone 1F4, catalog number: 201403), APC anti-rat CD45 (clone OX-33, catalog number: 202313), PE anti-rat CD8 (clone G28, catalog number: 200608), PE anti-rat CD161 (clone 3.2.3, catalog number: 205604), and PE / Cy7 anti-rat CD4 (clone W3 / 25, catalog number: 201520). Enzyme-linked immunosorbent assay (ELISA) kits: rat tumor necrosis factor α (TNF-α, brand: Dayu, catalog number: 1317202) and interferon γ (IFN-γ, brand: Dayu, catalog number: 1310002).
[0084] Example 1: Preparation and characterization of calcium carbonate / gelatin embolic microspheres
[0085] (1) Preparation and characterization of crystalline calcium carbonate nanoparticles
[0086] Calcium carbonate nanoparticles were prepared by carbon dioxide bubbling carbonization method, the main steps of which are as follows: add an equal volume of sodium hydroxide aqueous solution (2.4M) to 1L calcium chloride aqueous solution (1.2M), stir and mix for 5 minutes, and then introduce carbon dioxide gas into the mixed system until the solution is neutral and the gas introduction is stopped when the pH is 7.0. Collect by centrifugation (1500rpm, 3min), then wash the collected precipitate by centrifugation 3 times with ultrapure water, and collect by freeze-drying to obtain calcium carbonate nanoparticle powder for use.
[0087] The results of scanning electron microscopy of calcium carbonate nanoparticles are shown in Figure 1 As shown, the results show that the prepared calcium carbonate nanoparticles are uniform in size and monodisperse, with a particle size of about 100 nm.
[0088] (2) Preparation and characterization of calcium carbonate / gelatin embolic microspheres
[0089] Calcium carbonate / gelatin embolic microspheres were prepared by a water-in-oil (w / o) dual-channel microfluidic method, with the following steps: a toluene solution containing 2.5% Span 80 (v / v) was used as the continuous phase (oil phase), and a gelatin aqueous solution (10 wt%) containing 1 wt% calcium carbonate nanoparticles was used as the dispersed phase (water phase). The continuous phase and the dispersed phase were loaded into syringes (continuous phase input tube, dispersed phase input tube), respectively, and then pumped into the microchannel using a syringe micropump, with a flow rate of 100 L min -1 and 10L min -1 , so that the dispersed phase is sheared by the continuous phase in a droplet generation tube of size 30G, and then the water-in-oil calcium carbonate / gelatin droplets discharged from the sample receiving tube are collected in a glass bottle containing 2.5% (v / v) Span 80 in ice toluene solution (4°C). After 1 hour of physical crosslinking, the above product is separated, rinsed with ethanol several times, and then immersed in glutaraldehyde ethanol solution (2.5% w / v), and then chemically crosslinked and cured at room temperature for 1 hour. The final calcium carbonate / gelatin embolic microspheres are washed with ethanol several times, freeze-dried overnight under vacuum, and stored at 4°C for use.
[0090] The optical microscopy results of calcium carbonate / gelatin embolic microspheres are shown in Figure 2. Figure 2 As shown, the results showed that the calcium carbonate / gelatin embolic microspheres were uniform in size, with a particle size of 182.0±18.5 μm.
[0091] Scanning electron microscopy and elemental spectra of calcium carbonate / gelatin embolic microspheres Figure 3 As shown, the results showed that calcium carbonate nanoparticles were uniformly dispersed on the surface of calcium carbonate / gelatin embolic microspheres, and the microspheres had C, O, and Ca ion signals, further proving the presence of calcium carbonate.
[0092] (3) Preparation and characterization of gelatin embolic microspheres
[0093] The preparation method is basically the same as step (2), except that: gelatin embolic microspheres can be prepared without adding 1 wt % calcium carbonate nanoparticles into the aqueous phase.
[0094] The results of scanning electron microscopy of gelatin embolic microspheres are shown in Figure 4 As shown, the results showed that the obtained gelatin embolic microspheres were relatively uniform in size, with a particle size of 266.8±21.2μm.
[0095] (4) Preparation and characterization of calcium carbonate / gelatin embolic microspheres of different sizes
[0096] The preparation method is basically the same as step (2), with the only difference being that the size of the microfluidic droplet generation tube (30G) is changed to 21G, 22G, 25G and 27G, respectively, to obtain calcium carbonate / gelatin embolic microspheres of different sizes.
[0097] Optical microscopy results of calcium carbonate / gelatin embolic microspheres of different sizes are shown in Figure 2. Figure 5 As shown, the results showed that the particle size of calcium carbonate / gelatin embolic microspheres decreased with the decrease of channel size, and the particle sizes were 764.3±21.5μm (droplet generating tube size was 21G), 720.2±22.7μm (droplet generating tube size was 22G), 427.3±24.1μm (droplet generating tube size was 25G), 327.5±36.4μm (droplet generating tube size was 27G) and 182.0±18.5μm (droplet generating tube size was 30G).
[0098] (5) Performance test of calcium carbonate / gelatin embolic microspheres
[0099] The water absorption rate and further swelling rate of calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres in (2) and (3) were tested respectively. Figure 6-7 The results showed that the water absorption rates of calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres were 346.8% and 336.2%, respectively. Figure 6 ), the swelling ratios were 52.8% and 64.2% ( Figure 7 ), there was no statistical difference between the two, indicating that the addition of calcium carbonate had no significant effect on the water absorption and swelling properties of gelatin embolic microspheres.
[0100] (6) Study on the calcium ion release ability of calcium carbonate / gelatin embolic microspheres
[0101] In order to study the calcium ion release ability of calcium carbonate / gelatin embolic microspheres under slightly acidic conditions, the calcium carbonate / gelatin embolic microspheres prepared in (2) were co-incubated with PBS buffer solutions of different pH values (pH 7.4, pH 7.0, pH 6.8, and pH 6.5). The supernatant of the solution was collected at different time points, and the Ca 2+ release rate was determined by inductively coupled plasma optical emission spectrometry (ICP-OES). 2+ The results are as follows Figure 8 As shown, the results showed that the Ca2+ of calcium carbonate / gelatin embolic microspheres 2+ The release amount increased with the decrease of buffer pH, indicating that the calcium carbonate in the calcium carbonate / gelatin embolic microspheres dissociated under acidic conditions, leading to the release of calcium ions.
[0102] (7) Study on the proton neutralization ability of calcium carbonate / gelatin embolic microspheres
[0103] In order to study the proton neutralization ability of calcium carbonate / gelatin embolic microspheres, the calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres prepared in (2) and (3) were dissolved in a hydrochloric acid aqueous solution with a pH of 6.5, respectively. The pH changes of the solutions were monitored in real time by a pH microelectrode (PreSens, Germany). The results are shown in Figure 2. Fig. 9 As shown, the results showed that calcium carbonate / gelatin embolic microspheres could significantly increase the pH value of the solution compared with gelatin embolic microspheres, indicating that calcium carbonate / gelatin embolic microspheres could effectively neutralize microacids.
[0104] Example 2: Calcium carbonate / gelatin embolic microspheres for thrombin loading and in vitro performance testing
[0105] (1) Calcium carbonate / gelatin embolic microspheres loaded with thrombin
[0106] First, thrombin (20 U mL -1 ) was dissolved in 4-hydroxyethylpiperazineethanesulfonic acid (HEPES) buffer (50 mM, 0.14 M NaCl, pH 7.6), and then fully mixed with freeze-dried calcium carbonate / gelatin embolic microspheres (unless otherwise specified, the subsequent examples used the calcium carbonate / gelatin embolic microspheres prepared in step (2) of Example 1) (15 mg). After incubation at room temperature for 2 h, the microspheres were rinsed three times with HEPES buffer to obtain thrombin@calcium carbonate / gelatin embolic microspheres, which were then freeze-dried and stored at 4° C. for later use.
[0107] (2) Gelatin embolic microspheres loaded with thrombin
[0108] The preparation method is basically the same as step (1), except that the calcium carbonate / gelatin embolic microspheres are replaced with gelatin embolic microspheres to prepare thrombin@gelatin embolic microspheres.
[0109] The loading efficiency of calcium carbonate / gelatin embolic microspheres and gelatin embolic microspheres for thrombin Fig.10 As shown, the results showed that the loading rate of calcium carbonate / gelatin embolic microspheres was 47.6±2.04%, which was higher than 36.8±3.12% of gelatin embolic microspheres, indicating that the addition of calcium carbonate improved the loading efficiency of gelatin embolic microspheres for thrombin.
[0110] (3) Study on the release of thrombin@calcium carbonate / gelatin embolic microspheres
[0111] In order to study the release of thrombin from thrombin@calcium carbonate / gelatin embolic microspheres and thrombin@gelatin embolic microspheres under slightly acidic conditions, thrombin was first fluorescently labeled with the fluorescent dye FITC. Subsequently, the fluorescently labeled thrombin@calcium carbonate / gelatin embolic microspheres and thrombin@gelatin embolic microspheres were co-incubated with PBS buffer solutions of different pH values (pH 7.4, pH 7.0, pH 6.8, and pH 6.5), and the supernatant of the solution was collected at different time points, and the release of thrombin was detected by fluorescence. The results are shown in Figure 2. Figure 11-12 As shown in Figure 2, after 24 h of co-incubation, thrombin@CaCO3 / gelatin embolic microspheres released 53.2±2.85% ( Fig.11 ), which was significantly higher than 26.0±1.53% of thrombin@gelatin embolic microspheres ( Fig.12 ), the above results indicate that thrombin@calcium carbonate / gelatin embolic microspheres have slightly acid-responsive thrombin release ability.
[0112] (4) Blood compatibility analysis of calcium carbonate / gelatin embolic microspheres
[0113] To investigate the blood compatibility of calcium carbonate / gelatin embolic microspheres, fresh blood from rats was mixed with calcium carbonate / gelatin embolic microspheres at a concentration of 1.25 mg mL -1 -5mg mL -1 , and then perform a standard hemolysis test, the results are as follows Fig.13 The results showed that calcium carbonate / gelatin embolic microspheres could be used at concentrations up to 5 mg mL -1 In the case of , the hemolysis rate was only 0.37%, indicating that it has good blood compatibility.
[0114] (5) Cytotoxicity evaluation of calcium carbonate / gelatin embolic microspheres
[0115] To investigate the cytotoxicity of calcium carbonate / gelatin embolic microspheres, mouse H22 and rat N1S1 hepatoma cells were incubated with different concentrations of calcium carbonate / gelatin embolic microspheres for 24 h, and their cell viability was measured by a standard CCK-8 assay. Fig.14 As shown, the results showed that at a concentration of 2.5 mg mL -1 Under the condition of , the survival rates of the two groups of cells were 77.1% and 85.5%, respectively, with no obvious cytotoxicity, indicating that it has good biocompatibility.
[0116] (6) Evaluation of the synergistic procoagulant performance of thrombin and calcium ions
[0117] Experimental groups:
[0118] Example 2.6.1: Normal saline;
[0119] Example 2.6.2: Calcium chloride (concentration: 5 mM);
[0120] Example 2.6.3: Thrombin (concentration: 1.25 U);
[0121] Example 2.6.4: Thrombin + calcium chloride (concentration: 5 mM, 1.25 U).
[0122] In order to evaluate the ability of thrombin and calcium ions to promote blood coagulation, the anticoagulant EDTA-2K (2mM) was added to fresh rat blood to obtain anticoagulated blood. First, the ability of calcium chloride, thrombin and a mixture of the two to promote blood coagulation was evaluated. 200μL of fresh anticoagulated blood was added to aqueous solutions containing different concentrations of calcium chloride, thrombin and a mixture of the two. After incubation at 37°C for 10 minutes, 6mL of distilled water was added to lyse non-coagulated red blood cells, and the changes in its absorption at 545nm (hemoglobin) were measured using a UV-visible spectrometer. The results are shown in Figure 2. Fig.15 As shown, the results show that the absorption of Example 2.6.2 and Example 2.6.3 are 0.092 and 0.065 respectively, while the absorption of Example 2.6.4 is only 0.026, which is significantly lower than that of Example 2.6.2 and Example 2.6.3, indicating that calcium chloride and thrombin can coordinately promote the coagulation process.
[0123] (7) Evaluation of the in vitro procoagulant performance of thrombin@calcium carbonate / gelatin embolic microspheres
[0124] In order to evaluate the procoagulant ability of thrombin@calcium carbonate / gelatin embolic microspheres, firstly, gelatin embolic microspheres, thrombin@gelatin embolic microspheres, calcium carbonate / gelatin embolic microspheres and thrombin@calcium carbonate / gelatin embolic microspheres (where Ca 2+ =5mM, thrombin =1.25U) were incubated with PBS buffer solutions of pH 6.5 and pH 7.4 for 4h. Then, the supernatant was collected and mixed with fresh anticoagulated blood (200μL). The procoagulant effect of thrombin@calcium carbonate / gelatin embolization microspheres was evaluated by the above experimental steps. The results are shown in Fig.16 As shown, the results showed that compared with the control group, after incubation under acidic conditions, thrombin@calcium carbonate / gelatin embolic microspheres could significantly promote coagulation due to the release of calcium ions and thrombin due to the dissociation of calcium carbonate structure, and the blood absorption value of non-coagulated blood was reduced to 0.018. Therefore, thrombin@calcium carbonate / gelatin embolic microspheres have the ability to promote blood in a slightly acid-responsive manner.
[0125] Example 3: Study on the application of thrombin@calcium carbonate / gelatin embolic microspheres in the arterial embolization therapy of rat liver cancer
[0126] (1) Establishment of an in situ liver cancer model in SD rats
[0127] Male SD rats, with an average body weight of 300 g to 350 g, were used. During the inoculation of tumors, the rats were anesthetized by inhalation of isoflurane. To inoculate orthotopic N1S1 liver tumors, the left liver lobe of the rats was first exposed surgically, and then a total of 75 μL containing 6 × 10 6 The PBS / matrigel mixture (v / v=2:1) of N1S1 cells was used. Seven days after tumor inoculation, the changes in tumor volume were recorded by T1-weighted enhanced magnetic resonance (MR) imaging under a 3.0T magnetic resonance scanner. At the same time, MR imaging was used to measure the maximum diameter of the tumor in the superior-inferior (SI), lateral-medial (LM) and anterior-posterior (AP) planes. The tumor volume was calculated according to the formula: V=4 / 3×π×1 / 2SI×1 / 2LM×1 / 2AP.
[0128] (2) Study on transarterial embolization therapy with thrombin@calcium carbonate / gelatin embolic microspheres
[0129] Experimental groups:
[0130] Example 3.2.1: 200 μL of normal saline was injected into the hepatic artery via a catheter;
[0131] Example 3.2.2: 200 μL of 50% v / v gelatin embolic microsphere solution was injected into the hepatic artery via catheter;
[0132] Example 3.2.3: 200 μL of 50% v / v thrombin@gelatin embolic microsphere solution was injected into the hepatic artery via catheter;
[0133] Example 3.2.4: 200 μL of 50% v / v calcium carbonate / gelatin embolic microsphere solution was injected into the hepatic artery via catheter;
[0134] Example 3.2.5: 200 μL of 50% v / v thrombin@calcium carbonate / gelatin embolic microsphere solution was injected into the hepatic artery via catheter.
[0135] When the tumor volume reaches about 500 mm 3 At 14:00, rats were anesthetized with isoflurane, and a 3-cm midline incision was surgically opened to expose the tumor-containing liver lobe. Subsequently, the Y-shaped structure of the gastroduodenal artery, common hepatic artery, and proper hepatic artery was carefully identified under a stereomicroscope, and the gastroduodenal artery was isolated and ligated at its distal end. After transient ligation of the common hepatic artery, the gastroduodenal artery was cut with microdissecting scissors, and a PE-50 tube (0.6 mm) was retrogradely cannulated into the appropriate hepatic artery to fix the catheter, through which the above-mentioned microspheres were slowly injected into the appropriate hepatic artery. Afterwards, the upper end of the ruptured gastroduodenal artery was ligated with a 4-0 silk loop, and the common hepatic artery was released to restore intrahepatic arterial blood flow. The concentrations of calcium carbonate and thrombin in the microspheres were 1.1 mg kg -1and 30U kg -1 On days 3, 7, and 14 after embolization therapy, the changes in tumor volume of each rat were monitored by magnetic resonance imaging, and the changes in body weight of the rats were recorded.
[0136] (3) At 4 h after the same embolization treatment as in (2) above, one rat was taken from each group, and its tumor was collected and analyzed by hematoxylin / eosin (H&E) staining experiment to evaluate the ability of different treatment groups to induce tumor thrombosis.
[0137] (4) On the first day after the same embolization treatment as in (2) above, three rats were selected from each group and injected intratumorally with the pH-sensitive dye BCECF (20 μM, 100 μL). One hour later, the tumor tissues were collected and tumor imaging was performed using a small animal in vivo imaging system (excitation wavelength = 440 nm and 480 nm, emission wavelength = 520 nm) to evaluate the ability of different treatment groups to neutralize tumor microacidity.
[0138] The above results are Figure 17-19 As shown:
[0139] The tumor growth curve shows that the tumor volume of Example 3.2.5 is significantly lower than that of Examples 3.2.1-3.2.4, indicating that thrombin@calcium carbonate / gelatin embolic microsphere embolization therapy can greatly inhibit tumor growth ( Fig.17 ).
[0140] The results of H&E staining of tumor sections showed that the thrombin@calcium carbonate / gelatin microsphere embolization therapy in Example 3.2.5 could induce the formation of thrombus in the tumor, and obvious fibrin clots and tumor necrosis could be observed in the hepatic artery ( Fig.18 ).
[0141] The results of BCECF fluorescence ratio showed that after embolization with calcium carbonate / gelatin embolic microspheres in Example 3.2.4 and thrombin@calcium carbonate / gelatin embolic microspheres in Example 3.2.5, the pH in the tumor was significantly increased ( Fig.19 ).
[0142] Example 4: Validation of Thrombin@Calcium Carbonate / Gelatin Embolic Microsphere Embolic Therapy to Activate the Body's Immune Response Experimental Grouping:
[0143] Example 4.1: 200 μL of normal saline was injected into the hepatic artery via a catheter;
[0144] Example 4.2: 200 μL of 50% v / v gelatin embolic microsphere solution was injected into the hepatic artery via a catheter;
[0145] Example 4.3: 200 μL of 50% v / v thrombin@gelatin embolic microsphere solution was injected into the hepatic artery via a catheter;
[0146] Example 4.4: 200 μL of 50% v / v calcium carbonate / gelatin embolic microsphere solution was injected into the hepatic artery via catheter;
[0147] Example 4.5: 200 μL of 50% v / v thrombin@calcium carbonate / gelatin embolic microsphere solution was injected through the hepatic artery via catheter.
[0148] To investigate the immunostimulatory effect of thrombin@calcium carbonate / gelatin embolic microspheres after embolic therapy, N1S1 tumor-bearing rats were randomly divided into five groups, three rats in each group, and received embolic therapy in the above five groups. The concentrations of calcium carbonate and thrombin in the microspheres were 1.1 mg kg -1 and 30Ukg -1 On day 3 after embolization, the rats were sacrificed, and the tumors were collected and homogenized to obtain single-cell suspensions, and the intratumoral CD8 + T cells (CD45 + CD3 + CD8 + ) and NK cells (CD45 + CD3 + CD161 + In addition, the secretion levels of TNF-α and IFN-γ in tumor lysate and serum were analyzed using corresponding ELISA kits. The results are as follows Figure 20-24 As shown, the results show that the thrombin@calcium carbonate / gelatin embolic microsphere embolization therapy in Example 4.5 can significantly increase the CD3 + CD8 + T lymphocytes ( Fig. 20 ) and NK cells ( Fig.21 ) content. In addition, the study showed that the thrombin@calcium carbonate / gelatin embolic microspheres in Example 4.5 increased the secretion levels of IFN-γ in the tumor and IFN-γ and TNF-α in the serum ( Figure 22-24 ). These results indicate that the thrombin@calcium carbonate / gelatin embolic microsphere embolization therapy in Example 4.5 can induce an effective anti-tumor immune response and further improve the therapeutic effect of tumor embolization.
[0149] In summary, the overall mechanism of action of thrombin@calcium carbonate / gelatin embolic microspheres is as follows: after transcatheter hepatic artery embolization, thrombin@calcium carbonate / gelatin embolic microspheres first block the aorta and then trigger thrombin and Ca carbonate in the slightly acidic environment of the tumor. 2+The calcium carbonate nanoparticles can also neutralize tumor microacids, thereby further activating anti-tumor immune responses. Therefore, thrombin@calcium carbonate / gelatin embolic microspheres can achieve comprehensive embolization of tumor vessels of different sizes and regulation of microacid environments by combining aortic interventional embolization with microvascular coagulation, and can be used for efficient interventional embolization and coagulation combined treatment of in situ liver cancer ( Fig.25 ).
[0150] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A procoagulant @ calcium carbonate / gelatin embolic microsphere, characterized in that: It comprises a procoagulant and calcium carbonate / gelatin embolic microspheres; the procoagulant is loaded into the calcium carbonate / gelatin embolic microspheres by adsorption, and the calcium carbonate / gelatin embolic microspheres comprise gelatin microspheres and calcium carbonate nanoparticles distributed in the gelatin microspheres; The particle size of the calcium carbonate / gelatin embolic microspheres is 100 μm-800 μm; the particle size of the calcium carbonate nanoparticles is 80 nm-200 nm; The procoagulant is selected from one or more of a vascular blocking agent, a truncated tissue factor and thrombin.
2. The procoagulant @ calcium carbonate / gelatin embolic microspheres according to claim 1, characterized in that: The vascular blocking agent is one or more selected from DMXAA, combretin A4 phosphate, flavone-8-acetic acid, plinabulin and omeprazole; the truncated tissue factor is one or more selected from MHCII antibody-tTF fusion protein, vascular endothelial cell adhesion factor antibody-tTF fusion protein, fibronectin antibody-tTF fusion protein, polypeptide-tTF fusion protein; The thrombin is derived from one or more of human plasma, bovine plasma, rabbit plasma and rat plasma.
3. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 1 or 2, characterized in that: A microchannel reactor is used as a generating device, the microchannel reactor comprises a droplet generating tube, a dispersed phase input tube and a continuous phase input tube connected to the input end of the droplet generating tube, and a sample receiving tube connected to the output end of the droplet generating tube; the preparation method comprises the following steps: S1, dissolving calcium carbonate nanoparticles in gelatin solution to obtain a dispersed phase; Adding a surfactant to the oil phase to obtain a continuous phase; S2, injecting the dispersed phase and the continuous phase described in S1 into the dispersed phase input tube and the continuous phase input tube respectively, so that the dispersed phase is sheared by the continuous phase in the droplet generation tube to obtain water-in-oil calcium carbonate / gelatin droplets; S3, adding a cross-linking agent to the water-in-oil calcium carbonate / gelatin droplets described in S2 for solidification, and obtaining calcium carbonate / gelatin embolic microspheres by freeze-drying; S4. Add the calcium carbonate / gelatin embolic microspheres described in S3 to the procoagulant solution, and obtain the procoagulant@calcium carbonate / gelatin embolic microspheres after incubation.
4. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S1, the preparation of the calcium carbonate nanoparticles specifically includes the following steps: adding an equal volume of alkali solution to a calcium chloride solution, mixing and introducing carbon dioxide gas until the mixed solution is neutral, and obtaining the calcium carbonate nanoparticles by centrifugation, washing and freeze-drying.
5. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S1, the concentration of the gelatin solution is 5wt%-15wt%; the concentration of the calcium carbonate nanoparticles in the dispersed phase is 0.5wt%-5wt%; and the concentration of the surfactant in the continuous phase is 2wt%-10wt%.
6. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S1, the surfactant is selected from one or more of Span 80, Span 60, Span 40, Span 20, Tween 20, sodium dodecyl sulfate, sodium dodecylbenzene sulfonate, sodium oleate, lauryl alcohol polyoxyethylene ether and zinc stearate; the oil phase is selected from one or more of benzene, toluene, xylene, paraffin oil, petroleum ether, dodecane and hexadecane.
7. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S2, the flow rate of the continuous phase is 100 Lmin -1 -300Lmin -1 ; The flow rate of the dispersed phase is 10Lmin -1 -30Lmin -1 .
8. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S3, the cross-linking agent is one or more of formaldehyde, glutaraldehyde and genipin; the amount of the cross-linking agent is 2wt%-10wt% of the water-in-oil calcium carbonate / gelatin droplets.
9. The method for preparing the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 3, characterized in that: In S4, the concentration of the procoagulant solution is 5 U mL -1 -30UmL -1 .
10. Use of the procoagulant@calcium carbonate / gelatin embolic microspheres according to claim 1 or 2 in the preparation of an in situ liver cancer embolic therapeutic agent.
Citation Information
Cited By
Zeolite polyvinyl alcohol organic-inorganic composite embolization microsphere as well as preparation method and application thereof
CN121243448A
